Weekly News Roundup — Biosimilar Policy Changes, mRNA Leadership Shifts, and Rare Disease Market Growth

episode

tHEORetically Speaking not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from tHEORetically Speaking

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap 11 min · 13 Jul 2026

All episodes from tHEORetically Speaking →

Report any issue

Source

Recorded13 Mar 2026

Publisherfeeds.buzzsprout.com

Handlerec:16897540

Show notes

This week’s tHEORetically Speaking News Roundup covers the FDA’s new guidance aimed at streamlining biosimilar development and reducing drug costs, leadership changes at BioNTech as its founders step down to launch a new mRNA venture, and projections that the global rare disease drug market could surpass $400 billion by 2032. We also explore the FDA’s launch of a new unified adverse event monitoring platform designed to modernize safety surveillance and improve transparency. Tune in for this concise recap of the key developments shaping the life sciences, HEOR, and market access landscape.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.